AXL, a receptor tyrosine kinase of the TAM family, has also emerged as a promising therapeutic target in advanced cancers, including CRC, due to its frequent overexpression and central role in cell proliferation, invasion, metastasis, epithelial–mesenchymal transition, angiogenesis, therapy resistance, immunosuppression and inflammation. Here, AXL is linked to colorectal carcinoma.